Reading HUMA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track HUMA free→Reading HUMA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track HUMA free→QuarterlyIQ Insights · HUMA
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Entry into a Material Definitive Agreement. On June 10 , 2026, Humacyte, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Barclays Capital Inc., BTIG, LLC and Titan Partners Group LLC, a division of American Capital Partners, LLC, as representatives of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale in an underwritten offering (the “Offering”), pursuant to which the Company agreed to is…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On May 4, 2026, Humacyte, Inc. (the “Company”) received a letter from the staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) providing notification that, for the 30 consecutive business days ended May 1, 2026, the bid price for the Company’s common stock, par value $0.0001 per share (the “Common Stock”), had closed below the minimum $1.00 per share requirement for continued listing o…
Entry into a Material Definitive Agreement. On April 21, 2026, Humacyte, Inc. (the “Company”) entered into the Third Amendment to Distribution Agreement (the “Amendment”) with Fresenius Medical Care Holdings, Inc. (“Fresenius”), to amend the Distribution Agreement, dated as of June 25, 2018, as amended, between the Company and Fresenius (the “Agreement”). Under the Agreement, Humacyte granted to Fresenius rights to develop and commercialize the Company’s 6 millimeter acellular tissue engineer…
Results of Operations and Financial Condition. The disclosure set forth under the caption "Operational Updates--Preliminary Financial Information for the Year Ended December 31, 2025" in Item 8.01, below, is incorporated herein by reference.
Entry into a Material Definitive Agreement. On March 19, 2026, Humacyte, Inc. (the “Company”) entered into certain securities purchase agreements (the “Purchase Agreements”) pursuant to which the Company agreed to issue and sell to certain investors in a registered direct offering (the “Offering”) 25,000,000 shares of the Company’s common stock, $0.0001 par value per share, at a price of $0.80 per share (the “Shares”). The net proceeds to the Company from the Offering are expected to be appro…
Other Events. Suspension and Termination of ATM Prospectus On March 19, 2026, Humacyte, Inc. (the “Company”) delivered written notice to TD Securities (USA) LLC, as agent (“TD Cowen”), that it was suspending and terminating the prospectus, dated December 16, 2025 (the “ATM Prospectus”), relating to the sale of up to $60 million of the Company’s common stock, par value $0.0001 per share (“Common Stock”), that may be issued and sold pursuant to the Sales Agreement, dated as of December 16, 2025…
Entry into a Material Definitive Agreement On December 16, 2025, Humacyte, Inc. (the “Company”) entered into a Sales Agreement (the “Agreement”) with TD Securities (USA) LLC, as agent (“TD Cowen”), under which the Company may offer and sell its common stock, par value $0.0001 per share, from time to time having an aggregate offering price of up to $60 ,000,000 (the “Shares”) during the term of the Agreement through TD Cowen, acting as agent. The Company has filed a prospectus supplement relat…
Termination of a Material Definitive Agreement On December 15, 2025, the Humacyte, Inc. (the “Company”) and Humacyte Global, Inc. (“Global”) agreed with TPC Investments III LP and TPC Investments Solutions LP (collectively, the “Purchasers”), and Hook SA LLC, as agent for the Purchasers (the “Purchasers’ Agent”), to terminate the Revenue Interest Purchase Agreement, dated as of May 12, 2023, as amended (the “Purchase Agreement”), by and among the Company, Global, the Purchasers and the Purcha…
Unregistered Sales of Equity Securities. The disclosure regarding the Warrant set forth above under the
Entry into a Material Definitive Agreement On December 15, 2025 (the “Closing Date”), Humacyte, Inc. (the “Company”) and Humacyte Global, Inc. (“Global”, and together with the Company, the “Borrowers”), a wholly-owned subsidiary of the Company, entered into a loan and security agreement (the “Loan Agreement”) with Avenue Venture Opportunities Fund II, L.P., as administrative agent and collateral agent for the lenders (the “Loan Agent”) and as lender (“Avenue”), which provides for a senior sec…
Creation of a Direct Financial Obligation. The disclosure regarding the Loan Agreement set forth above under the
Termination of a Material Definitive Agreement As previously disclosed, on September 1, 2022, Humacyte, Inc. (the “Company”) entered into an Open Market Sale Agreement™ (the “Agreement”) with Jefferies LLC (“Jefferies”), under which the Company may offer and sell its common stock, par value $0.0001 per share, from time to time having an aggregate offering price of up to $80,000,000 during the term of the Agreement through Jefferies, acting as agent. On November 21, 2025, the Company delivered…
Results of Operations and Financial Condition On November 12, 2025, Humacyte, Inc. issued a press release regarding its financial results for its fiscal third quarter ended September 30, 2025. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. The information contained herein, including the exhibit attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as am…
Entry into a Material Definitive Agreement On October 6, 2025, Humacyte, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”), pursuant to which the Company agreed to issue and sell to certain investors in a registered direct offering (the “Offering”) (i) 28,436,018 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), and (ii) warrants to purchase up to 28,436,018 shares of Common Stock (the “Warrants”).…
Entry into a Material Definitive Agreement As part of a planned refinancing of certain debt obligations, on September 17, 2025, Humacyte, Inc. (the “Company”) and Humacyte Global, Inc., a wholly owned subsidiary of the Company (“Global”), entered into Amendment No. 2 to the Revenue Interest Purchase Agreement (the “Amendment”) with TPC Investments III LP and TPC Investment Solutions LP (collectively, the “Purchasers”) and Hook SA LLC, as agent for the Purchasers (the “Agent”), to amend the Re…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant The disclosure set forth above under the
Results of Operations and Financial Condition On August 11, 2025, Humacyte, Inc. issued a press release regarding its financial results for its fiscal second quarter ended June 30, 2025. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. The information contained herein, including the exhibit attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended…
Results of Operations and Financial Condition On May 13, 2025, Humacyte, Inc. issued a press release regarding its financial results for its fiscal first quarter ended March 31, 2025. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. The information contained herein, including the exhibit attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (th…
Results of Operations and Financial Condition On March 28, 2025, Humacyte, Inc. issued a press release regarding its financial results for its fiscal fourth quarter and full year ended December 31, 2024. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. The information contained herein, including the exhibit attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of…
Entry into a Material Definitive Agreement. On March 25, 2025, Humacyte, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with TD Securities (USA) LLC, Barclays Capital Inc. and BTIG, LLC, as representatives of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale in an underwritten offering (the “Offering”) of 25,000,000 shares of the Company’s common stock, $0.0001 par value per share, at a pric…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.